Abstracts Archive - Page 1578 of 2425 - ACR Meeting Abstracts

Abstract Number: 2413 • 2016 ACR/ARHP Annual Meeting
Inflammation Regulating microRNAs, Mir-146b, Mir-155 and Mir-192-5p Are Altered in Plasma and Synovial Fluid of Oligoarticular Juvenile Idiopathic Arthritis
Beata Derfalvi^1,2,3, Sarah Roberts⁴, Breanna Hargreaves⁴ and Sarah McAlpine⁴, ¹Pediatrics, Dalhousie University, Halifax, NS, Canada, ²IWK Health Centre, Halifax, NS, Canada, ³2nd. Dept. of Pediatrics, Semmelweis University, Budapest, Hungary, ⁴Dalhousie University, Halifax, NS, Canada
Background/Purpose: MicroRNAs (miRNAs) modulate gene expression by inhibiting the translation of targeted mRNAs and causing mRNA degradation in a transcript-specific manner. Several miRNAs have been reported…
Abstract Number: 2414 • 2016 ACR/ARHP Annual Meeting
Microrna Associated with Active Systemic Juvenile Idiopathic Arthritis Regulate CD163 Expression in Polarized Macrophages through Two Distinct Mechanisms
Thuy Do¹, Rachel Tan², Mark Bennett², Mario Medvedovic², Nan Shen³, Sherry Thornton¹, Alexei Grom¹ and Grant Schulert⁴, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²University of Cincinnati, Cincinnati, OH, ³Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: CD163 is a hemoglobin scavenger receptor and innate pattern recognition receptor, and a marker of activated monocytes and macrophages. It is also expressed on…
Abstract Number: 2415 • 2016 ACR/ARHP Annual Meeting
Next Generation Sequencing Analysis of Familial Haemophagocytic Lymphohistiocytosis (HLH) Related Genes in Macrophage Activation Syndrome (MAS) and Secondary HLH (secHLH)
Chiara Passarelli¹, Manuela Pardeo², Elisa Pisaneschi¹, Antonio Novelli¹, Fabrizio De Benedetti² and Claudia Bracaglia², ¹Ospedale Pediatrico Bambino Gesù IRCCS, Unit of Medical Genetics, Laboratory of Cytogenetics and Molecular Genetics, Rome, Italy, ²Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy
Background/Purpose: Macrophage activation syndrome (MAS) is a severe complication of rheumatic disease, particularly of systemic JIA (sJIA). It is currently classified among the secondary forms…
Abstract Number: 2416 • 2016 ACR/ARHP Annual Meeting
Antibodies to Citrullinated Peptides in Patients with Juvenile Idiopathic Arthritis and Rheumatoid Arthritis: Shared Expression of the Inherently Autoreactive 9G4 Idiotype
Hannah Peckham¹, Lauren Bourke¹, Anna Radziszewska¹, Maria J. Leandro², Debajit Sen¹, Geraldine Cambridge² and Yiannis Ioannou¹, ¹Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Rheumatoid factor (RF) positive polyarticular JIA (RF+ve pJIA) frequently progresses into adulthood with a clinical phenotype that ressembles rheumatoid arthritis (RA). Antibodies to cyclic…
Abstract Number: 2417 • 2016 ACR/ARHP Annual Meeting
High Dimensional Interrogation of the T Cell Immunome in Polyarticular Juvenile Idiopathic Arthritis Patients
Jing Yao Leong¹, Justin Tiong², Joo Guan Yeo^2,3, Liyun Lai¹, Phyllis Chen³, Loshinidevi D/O Thana Bathi³, Thaschawee Arkachaisri², Daniel J Lovell⁴ and Salvatore Albani^1,5, ¹SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ²Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ³Singhealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ⁴PRCSG Cincinnati Children's Hospital Medical Center, Cinncinnati, OH, ⁵Duke-National University of Singapore Medical School, Singapore, Singapore
Background/Purpose: Clinical management of polyarticular JIA with anti-TNF-alpha has been met with moderate success, with up to 50% of patients demonstrating clinically meaningful efficacy. Concerns…
Abstract Number: 2418 • 2016 ACR/ARHP Annual Meeting
Rnaseq Reveals Treatment-Associated Gene Expression Dynamics in Juvenile Idiopathic Arthritis CD4+ T Cells
Kaiyu Jiang¹, Lai Ping Wong¹, Yanmin Chen¹ and James Jarvis², ¹Pediatrics, University at Buffalo, Buffalo, NY, ²Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY
Background/Purpose: While the field of pediatric rheumatology has made enviable strides in improving the lives of children with juvenile idiopathic arthritis (JIA), there is still…
Abstract Number: 2419 • 2016 ACR/ARHP Annual Meeting
Single-Cell Analysis of CD163 mRNA and Protein Expression By Primeflow™ in Polarized Monocyte and Macrophage Populations
Rachel Tan¹, Sherry Thornton², Alyssa Sproles², Thuy Do³, Jonathan Schick⁴, Monica DeLay⁴ and Grant Schulert⁵, ¹University of Cincinnati, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati, OH, ⁵Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: CD163 is involved in the regulation and resolution of innate inflammation and the removal of free hemoglobin from the blood via internalization of the…
Abstract Number: 2420 • 2016 ACR/ARHP Annual Meeting
Investigating Genome-Wide Inbreeding Coefficients and Age of Diagnosis in a Multi-Ethnic Population of Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Chen Di Liao¹, Deanna Morra¹, Daniela Dominguez¹, Shazia Ali¹, Deborah M. Levy², Earl Silverman³, Andrew Paterson¹ and Linda T Hiraki¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Genetics plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). Up to 20% of those affected with SLE are diagnosed in…
Abstract Number: 2421 • 2016 ACR/ARHP Annual Meeting
Cell-Bound Complement Activation Products Correlate with Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Joyce Hui-Yuen¹, Derren Barken², John Conklin³, Tyler O'Malley⁴, Andrew Eichenfield⁵, Amy Starr⁶, Lisa F. Imundo⁷, Thierry Dervieux⁸ and Anca D. Askanase⁹, ¹North Shore-Long Island Jewish Health System, Lake Success, NY, ²Exagen Diagnostics, Inc., Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴Research and Development, Exagen Diagnostics, Vista, CA, ⁵Morgan Stanley Children's Hospital of NY-Presbyterian, Columbia University, New York, NY, ⁶Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ⁷Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY, ⁸Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁹Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CB-CAPs) have been demonstrated to be sensitive and…
Abstract Number: 2422 • 2016 ACR/ARHP Annual Meeting
Cyclic Amp, Erk5, and Transdifferentiation of Cardiac Fibroblasts in the Pathogenesis of Autoimmune Congenital Heart Block
Androo Markham¹, Sara Rasmussen², Miki Blumenberg³, Robert M Clancy² and Jill P. Buyon¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Dermatology, NYU School of Medicine, New York, NY
Background/Purpose: Maternal autoantibodies (Ab) reactive with the Ro/La ribonucleoprotein complex are associated with the development of cardiac injury in a fetus passively exposed to these…
Abstract Number: 2423 • 2016 ACR/ARHP Annual Meeting
Differential Interferon Score Expression in the Peripheral Blood in Mendelian Inflammatory Interferonopathies Versus Juvenile Dermatomyositis (JDM) Subtyped By Myositis Autoantibodies and Disease Activity
Hanna Kim¹, Terrance P. O'Hanlon², Adriana Almeida de Jesus³, Yan Huang³, Ira N. Targoff^4,5, Frederick W. Miller², Raphaela Goldbach-Mansky⁶ and Lisa G. Rider², ¹NIAMS/NIH, Bethesda, MD, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: JDM is a complex autoimmune disease with an interferon (IFN) signature, with a reported correlation with disease activity. Clinical features vary among myositis-specific autoantibody…
Abstract Number: 2424 • 2016 ACR/ARHP Annual Meeting
Novel Autoantigens for Anti- Endothelial Cell Antibodies in Pediatric Rheumatic Diseases Identified By Proteomics
Rie Karasawa¹, Mayumi Tamaki¹, Toshiko Sato¹, Kazuo Yudoh² and James Jarvis³, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan, ³Pediatrics, The University at Buffalo, Buffalo, NY
Background/Purpose: Juvenile dermatomyositis (JDM), a systemic autoimmune vasculopathy, and juvenile idiopathic arthritis (JIA) are representative rheumatic diseases in children. However the pathogenesis of these diseases…
Abstract Number: 2425 • 2016 ACR/ARHP Annual Meeting
The Vasculopathy of Juvenile Dermatomyositis (JDM); Evidence of Persistent Endothelial Injury, Hypercoagulability, Subclinical Inflammation and Increased Arterial Stiffness
Charalampia Papadopoulou^1,2, Ying Hong¹, Petra Krol^1,2, Yiannis Ioannou³, Clarissa Pilkington^2,4,5, Hema Chaplin⁶, Stephanie Simou¹, Marietta Charakida⁷, Lucy R Wedderburn^5,8,9, Paul Brogan¹⁰ and Despina Eleftheriou^1,8,11, ¹Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ²Paediatric Rheumatology, Great Ormond Street Hospital NHS Trust, London, United Kingdom, ³Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁴Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁵Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ⁶Centre for Adolescent Rheumatology, Arthritis Research UK, London, United Kingdom, ⁷Vascular Physiology Unit, Institute of Cardiovascular Science , University College London, London, United Kingdom, ⁸Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁹Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ¹⁰Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ¹¹Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom
Background/Purpose: Vasculopathy is considered central to the pathogenesis of Juvenile Dermatomyositis (JDM). The interplay between persistent JDM-vasculopathy, traditional cardiovascular risk factors, exposure to corticosteroids, and…
Abstract Number: 2426 • 2016 ACR/ARHP Annual Meeting
Transcriptomic Analysis of Immune Subsets in Juvenile Dermatomyositis before and after Treatment Identifies Novel Pathways Involved in Pathogenesis
Claire Deakin¹, Georg Otto^2,3, Meredyth Wilkinson⁴, Stefanie Dowle^2,3, Stefania Simou⁵, Lucy Marshall⁶, Elizabeth Rosser⁶, Daniel Kelberman^2,3, Lucy R Wedderburn^6,7,8 and Juvenile Dermatomyositis Research Group (JDRG), ¹Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, ²Genetics & Genomic Medicine Programme, UCL Institute of Child Health, London, United Kingdom, ³National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ⁴Division of Medicine, University College London, London, United Kingdom, ⁵Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁶Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ⁷Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁸Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Background/Purpose: Although proximal muscle weakness and skin rash are the typical features of juvenile dermatomyositis (JDM), little is known about disease pathogenesis, why other features…
Abstract Number: 2427 • 2016 ACR/ARHP Annual Meeting
Identification of Biomarkers Using Tear Proteomics in Children with Chronic Anterior Uveitis
Sheila Angeles-Han^1,2, Duc Duong³, Steven Yeh⁴, Purnima Patel¹, Kirsten Jenkins², Sampath Prahalad^2,5 and Gary Holland⁶, ¹Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Emory University, Atlanta, GA, ⁴Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁵Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁶Jules Stein Eye Institute, Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Children with juvenile idiopathic arthritis (JIA) are at risk for anterior uveitis which can lead to ocular complications and vision loss. The ANA is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.